{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:52Z","timestamp":1707524632561},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,25]]},"DOI":"10.7759\/cureus.27249","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T20:18:45Z","timestamp":1658780325000},"source":"Crossref","is-referenced-by-count":0,"title":["Remdesivir-Induced Marked Sinus Bradycardia in COVID-19"],"prefix":"10.7759","author":[{"given":"Taimoor","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samra Haroon","family":"Lodhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"FDA approves first treatment for COVID-19. (2020). Accessed. October 29, 2020: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue ML","year":"2020","unstructured":"Holshue ML, DeBolt C, Lindquist S, et al.. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020, 382:929-936. 10.1056\/NEJMoa2001191","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11132","article-title":"Cardiac adverse events with remdesivir in COVID-19 infection","volume":"12","author":"Gupta AK","year":"2020","unstructured":"Gupta AK, Parker BM, Priyadarshi V, Parker J. Cardiac adverse events with remdesivir in COVID-19 infection. Cureus. 2020, 12:e11132. 10.7759\/cureus.11132","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2020.08.025","article-title":"Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review","volume":"2","author":"Gubitosa JC","year":"2020","unstructured":"Gubitosa JC, Kakar P, Gerula C, et al.. Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review. JACC Case Rep. 2020, 2:2260-2264. 10.1016\/j.jaccas.2020.08.025","journal-title":"JACC Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(92)91012-P","article-title":"Normal sinus heart rate: sinus tachycardia and sinus bradycardia redefined","volume":"124","author":"Spodick DH","year":"1992","unstructured":"Spodick DH. Normal sinus heart rate: sinus tachycardia and sinus bradycardia redefined. Am Heart J. 1992, 124:1119-1121. 10.1016\/0002-8703(92)91012-P","journal-title":"Am Heart J"},{"key":"ref6","unstructured":"Gilead Sciences. Veklury\u00ae (remdesivir) Use for Pediatric Patients. (2020). Accessed. October 29, 2020: http:\/\/2020."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu S","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey RT Jr, et al.. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019, 381:2293-2303. 10.1056\/NEJMoa1910993","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","volume":"382","author":"Grein J","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, et al.. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020, 382:2327-2336. 10.1056\/NEJMoa2007016","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020, 395:1569-1578. 10.1016\/S0140-6736(20)31022-9","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.7655","article-title":"Association of asymptomatic bradycardia with incident cardiovascular disease and mortality: the multi-ethnic study of atherosclerosis (MESA)","volume":"176","author":"Dharod A","year":"2016","unstructured":"Dharod A, Soliman EZ, Dawood F, Chen H, Shea S, Nazarian S, Bertoni AG. Association of asymptomatic bradycardia with incident cardiovascular disease and mortality: the multi-ethnic study of atherosclerosis (MESA). JAMA Intern Med. 2016, 176:219-227. 10.1001\/jamainternmed.2015.7655","journal-title":"JAMA Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2021-141079","article-title":"Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre","volume":"98","author":"Bistrovic P","year":"2022","unstructured":"Bistrovic P, Manola S, Lucijanic M. Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre. Postgrad Med J. 2022, 98:501-502. 10.1136\/postgradmedj-2021-141079","journal-title":"Postgrad Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.009811","article-title":"Remdesivir-induced bradycardia in COVID-19: a single center prospective study","volume":"14","author":"Attena E","year":"2021","unstructured":"Attena E, Albani S, Maraolo AE, et al.. Remdesivir-induced bradycardia in COVID-19: a single center prospective study. Circ Arrhythm Electrophysiol. 2021, 14:e009811. 10.1161\/CIRCEP.121.009811","journal-title":"Circ Arrhythm Electrophysiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/99308-remdesivir-induced-marked-sinus-bradycardia-in-covid-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:24Z","timestamp":1707507624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/99308-remdesivir-induced-marked-sinus-bradycardia-in-covid-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.27249","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,25]]}}}